<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003321</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-15961-40973</org_study_id>
    <secondary_id>EORTC-15961/40973</secondary_id>
    <nct_id>NCT00003321</nct_id>
  </id_info>
  <brief_title>Quality-of-Life Assessment of Patients Who Have Cancer of the Esophagus</brief_title>
  <official_title>An International Field Study of the Reliability and Validity of the EORTC-QLQ-C30 and a Disease Specific Questionnaire Module (the EORTC OES-24) in Assessing the Quality of Life of Patients With Oesophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Questionnaires that measure quality of life may improve the ability to plan
      treatment for patients who have cancer of the esophagus.

      PURPOSE: This clinical trial studies quality-of-life assessments of patients with cancer of
      the esophagus who are receiving treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Test the psychometric, clinical, and cross cultural validity and reliability
      of the quality-of-life questionnaire EORTC-QLQ-C30 (version 3.0) in conjunction with the
      esophageal cancer-specific module EORTC QLQ-OES-24 in patients with esophageal cancer.

      OUTLINE: This is a multicenter study. Patients are stratified by treatment (potentially
      curative vs purely palliative). Patients receiving potentially curative treatment are further
      stratified according to study treatment (esophagectomy alone vs esophagectomy plus adjuvant
      or neoadjuvant chemo/radiotherapy vs radical radiotherapy with or without chemotherapy).
      Patients receiving purely palliative treatment are further stratified according to study
      treatment (intubation/laser/ethanol injection vs palliative chemo/radiotherapy without
      endoscopic relief of dysphagia). Patients are administered two questionnaires: (1) The EORTC
      QLQ-C30 (version 3.0) is a 30-item questionnaire about patient ability to function, symptoms
      related to the cancer and its treatment, overall health and quality of life, and perceived
      financial impact of the cancer and its treatment. (2) The EORTC QLQ-OES-24 is a 24-item
      esophageal cancer-specific questionnaire supplementing EORTC QLQ-C30 with information about
      disease and treatment-related symptoms and side effects, dysphagia, nutrition, and social and
      emotional effects of esophageal cancer. Both questionnaires are administered once before and
      once during or after treatment.

      PROJECTED ACCRUAL: 370 patients (170 with locoregional disease, 200 with metastatic disease)
      will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1998</start_date>
  <primary_completion_date type="Actual">August 2001</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>psychosocial assessment and care</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Group I: Local or locoregional primary esophageal or
        esophago-gastric cancer Planned esophagectomy with or without adjuvant or neoadjuvant
        chemotherapy and/or radiotherapy OR Planned radical radiotherapy with or without
        chemotherapy Prior endoscopic procedure to relieve dysphagia allowed No distant liver or
        bone metastasis if undergoing esophagectomy Group II: Metastatic esophageal cancer or local
        anastomotic recurrence of esophageal cancer or deemed unsuitable for esophagectomy Prior
        palliation by endoscopic or open intubation, laser treatment, tumor necrosis with alcohol
        injection or diathermy, or intraluminal radiotherapy allowed Prior palliative radiotherapy
        or chemotherapy allowed No cerebral metastases

        PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Life expectancy:
        Group I: At least 3 months Group II: At least 4 weeks Hematopoietic: Not specified Hepatic:
        Not specified Renal: Not specified Other: Mentally fit to complete a questionnaire or
        undergo an interview Aware of diagnosis No concurrent second malignancy except basal cell
        skin cancer No concurrent participation in other quality-of-life studies

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics
        Surgery: See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Blazeby, MB, CHB, FRCS, BSc, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospitals Bristol NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital, Perth</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine De Radiologie</name>
      <address>
        <city>Saint Brieux</city>
        <zip>F-22015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Roessle Klinik</name>
      <address>
        <city>Berlin</city>
        <zip>D-13122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>D-35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonissehjemm Ets University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>N-5009</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg (Goteborg)</city>
        <zip>S-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Infirmary</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Conroy T, Etienne PL, Adenis A, Ducreux M, Paillot B, Oliveira J, Seitz JF, Francois E, Van Cutsem E, Wagener DJ, Kohser F, Daamen S, Praet M, Gorlia T, Baron B, Wils J; European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol. 2002 May;13(5):721-9.</citation>
    <PMID>12075740</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>March 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2004</study_first_posted>
  <last_update_submitted>June 11, 2013</last_update_submitted>
  <last_update_submitted_qc>June 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I esophageal cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

